



International  
Pandemic  
Preparedness  
Secretariat



# 100 Days Mission

## Launch of the Fifth Implementation Report

27<sup>th</sup> January 2026 – Paris, France

## Speaker Biographies

(in order of appearance)



International  
Pandemic  
Preparedness  
Secretariat



### Dr Mona Nemer



Dr. Mona Nemer is a distinguished scientist and strategic leader who presently serves as the Chief Science Advisor to Canada's Prime Minister and Cabinet. Her mandate is to provide advice on issues related to science and government policies that support it.

A leader in molecular cardiology, Dr. Nemer has discovered several genes essential for normal heart development and function. Her work has contributed to the development of diagnostic tests for heart failure and the genetics of cardiac birth defects.

Dr. Nemer continues to serve on several international advisory boards and is a sought-after speaker. She currently chairs the 100 Days Mission Steering Group, the governing body which oversees the work of the International Pandemic Preparedness Secretariat. Her accomplishment have been widely recognized by civilian and scientific honours. She is a Member of the Order of Canada, a fellow of the Academy of Sciences of the Royal Society of Canada, a fellow of the Chemical Institute of Canada, a fellow of the American Academy of Arts and Science, a Knight of the Ordre national du Québec, a Knight of the French Republic's National Order of Merit and a Knight of the National Order of the Legion of Honour. She is the recipient of several honorary doctorates from universities in Canada, France, Finland, Lebanon and the United States.



International  
Pandemic  
Preparedness  
Secretariat

**anrs**  
MALADIES INFECTIEUSES  
EMERGENTES Inserm

 **PASTEUR**  
NETWORK

**Ambassador Anne-Claire Amprou**



Anne-Claire AMPROU is the French Ambassador for Global Health. French negotiator for the international agreement on pandemic prevention, preparedness and response from 2022 to 2024, she then co-chaired the negotiations at the World Health Organization until the adoption of the pandemic agreement at the World Health Assembly in May 2025. Anne-Claire Amprou is involved in the governance of several global health initiatives, including the Global Fund to Fight AIDS, Tuberculosis and Malaria and the Pandemic Fund. In December 2025, she has also been appointed Chair of Unitaid.

These experiences give her a cross-cutting view of the global health ecosystem and priority issues. After starting her career as director of hospital, she joined the Inspectorate-General of Social Affairs. She was a member of the Ebola task force and then Deputy Director General for Health at the French Ministry of Solidarity and Health. Before coordinating the French response to the Covid-19 crisis in 2021, she was Chief General Manager of Universcience, a cultural and scientific institute.



International  
Pandemic  
Preparedness  
Secretariat



### Prof Didier Samuel



As a physician and a researcher, Prof. Didier Samuel was appointed Chairman and CEO of Inserm by the Council of Ministers meeting of 1 February 2023. As a doctor and a researcher, Didier Samuel has devoted himself to both fields throughout his career.

Professor of hepatology at the University of Paris-Saclay, director of the hepatology and hepatic resuscitation department at the Paul-Brousse hospital and medical director of the liver transplantation program within this same hospital, Didier Samuel took charge of and followed more than 4,500 liver transplant patients.

Dean of the Faculty of Medicine of the University of Paris-Saclay between 2017 and 2023, Professor Samuel chaired the Conference of Deans of Medicine between 2022 and 2023. He also chaired the French National Research Coordination Committee, until his appointment as CEO of Inserm.

Since 2005, Professor Didier Samuel led a research unit within Inserm devoted to physiopathogenesis and treatment of liver diseases. He chaired the International Society for Liver Transplantation between 2007 and 2015, and also the Journal of Hepatology between 2009 and 2014. His expertise in the field of liver diseases and liver transplantation is internationally renowned.



International  
Pandemic  
Preparedness  
Secretariat

anrs  
MALADIES INFECTIEUSES  
EMERGENTES Inserm

PASTEUR  
NETWORK

**Prof Yazdan Yazdanpanah**



Professor Yazdan Yazdanpanah, Director of the ANRS Emerging infectious disease, French Funding Agency, French Aviesan Institute of Immunology, Inflammation, Infectiology, and Microbiology; Co-Chair of the Global Research Collaboration for Infectious Disease Preparedness International Network (GLoPID-r); Head of Infectious Disease department at Bichat Claude Bernard Hospital, Paris. Trained in medicine, gastroenterology, and infectious diseases in France, he also holds an MSc in Epidemiology from the Harvard School of Public Health and a PhD in Public Health. His research focuses on the clinical epidemiology of HIV, viral hepatitis, and emerging infectious diseases, as well as the pharmaco-economics of antimicrobial therapies.

Professor Yazdanpanah has played a key role in structuring national and international research responses to emerging infectious threats and has published extensively in leading peer-reviewed journals.

**Dr Rebecca Grais**



Rebecca F. Grais is the Executive Director of the Pasteur Network. She previously worked as the Director of Research at Epicentre, an epidemiology and research satellite created by Médecins Sans Frontières, an international medical humanitarian organization. Her primary areas of interest focus on prevention of infectious diseases and emerging infections in low- and middle-income countries.

She has particularly focused on population-based studies of the effectiveness of public health interventions and efficacy trials of novel vaccines and therapeutic agents. An additional aspect of her work concerns professional development, mentoring and management training for underrepresented populations in scientific research to advance their individual careers and contribute to adapted healthcare innovations. Dr. Grais holds a doctorate, two masters degrees and a bachelor's degree from Johns Hopkins University. She holds a Habilitation à diriger des Recherches from the Faculté de Médecine Paris Saclay (France). She has published over 200 peer-reviewed publications, is a member of diverse scientific, funding and international organization committees and advisory groups with a focus on vaccine development trials, effectiveness and epidemiologic studies among vulnerable populations. She is also a member of the Strategic Advisory Group of Experts at WHO.



**Ms Shingai Machingaidze**



Shingai Machingaidze is an epidemiologist and public health specialist. She has developed and led public health and clinical research programs that build the capacity of Africa-based scientists and institutions in Africa. Her expertise includes strategic engagement, planning and support of large public health programmes; conducting and managing clinical trials and clinical research; managing research grants and finances; as well as managing strategic partnerships and engagements with national, regional and international agencies. She has published in leading scientific journals and is a member of several institutional, regional and global advisory boards including the Advisory Committee for the Clinical Trials Community and Co-Chair of the 100 Days Mission Science Technology Expert Group (STEG). She was previously the Ag. Chief Science Officer for Africa CDC as well as the CPHIA Secretariat Lead and currently serves at the Head of Africa Strategy and Engagement at CEPI.

**Dr Victor Dzau**



Victor J. Dzau, MD, is president of the US National Academy of Medicine, vice chair of the US National Research Council, chancellor emeritus of Duke University, and past CEO of Duke Health System. Previously, he was professor and chairman of medicine at both Harvard and Stanford Universities. Dzau is a physician scientist renowned for his research in cardiovascular medicine for his role in the development of life saving drug ACE inhibitors and his leadership in global health. He serves on WHO/World Bank Global Preparedness Monitoring Board and co-chairs the G20 High-Level Independent Panel on pandemic financing, the Regional Vaccine Manufacturing Collaborative, and the International Pandemic Preparedness Science and Technology Expert Panel. He was a principal of the ACT Accelerator, was co-chair of the G20 Scientific Panel on Global Health Security, served as an advisor to the G7 (Japan) Health Task Force, and served on the interim board of the Coalition of Epidemic Preparedness and Innovation (CEPI). Among his many honors and awards, he has been honored with the Order of the Rising Sun by Japan Emperor and Honorary Citizen by Singapore President, and 23 honorary doctorates.



International  
Pandemic  
Preparedness  
Secretariat

anrs  
MALADIES INFECTIEUSES  
EMERGENTES Inserm

PASTEUR  
NETWORK

**Dr Lindsay Keir**



A global health strategist and former paediatric clinician scientist with over 20 years of experience, Lindsay is driven by a commitment to equity, innovation, and improving lives through evidence-based action. Lindsay transitioned from clinical academia to global health to have a broader impact—working at the intersection of research, strategy, and policy to strengthen health systems and accelerate innovation for underserved communities.

Lindsay brings deep expertise in global health R&D across neglected diseases, emerging infectious threats, and maternal health. As a collaborative leader, she excels in strategy development, stakeholder engagement, and building high-performing teams. Her work has shaped global agendas, including leading the 100 Days Mission Scorecard which has informed G20 and other high level dialogues.

**Dr François Lacoste**



François Lacoste joined Institut Mérieux in 2024 as Executive Vice-President Medical and Scientific Affairs and he is a member of the Institut Mérieux Executive Committee.

From 2011 to 2024, he held the position of Executive Vice-President Research and Development at bioMérieux, where he was also a member of the Executive Committee. François Lacoste had joined the company in 2000.

Prior to joining bioMérieux, he held various management positions in R&D at Rhône Mérieux and Merial.

François Lacoste is a graduate of the National Veterinary College of Toulouse and holds post-graduate degrees in Virology from the Pasteur Institute, Paris, and in Immunology from the National Veterinary School, Maisons-Alfort. He also completed an Executive Management Course at INSEAD.



International  
Pandemic  
Preparedness  
Secretariat

**anrs**  
MALADIES INFECTIEUSES  
EMERGENTES Inserm

 PASTEUR  
NETWORK

<b>Dr Hala Audi</b> 	<p>Hala Audi heads partnerships at Quantoom Biosciences, a leader in nucleic acids innovation supporting access and autonomy in R&amp;D and bioproduction worldwide. From 2022 to 2025, Hala was the CEO of Unizima, working for clients establishing biomanufacturing capability in Africa and the Middle East across vaccines, monoclonal antibodies and insulin.</p> <p>Earlier in her career, Hala was a director in the UK Treasury and led the O'Neill Review on Antimicrobial Resistance on behalf of the UK Prime Minister, working with the Wellcome Trust, WHO, governments and industry.</p> <p>She holds degrees in law and public administration and serves as a member of the STEG of the International Pandemic Preparedness Secretariat.</p>
<b>Dr Phillippe Duneton</b> 	<p>A French national, Philippe has more than 25 years' experience in the fields of HIV/AIDS, infectious and tropical diseases and public health. Philippe has been at Unitaid since its creation in 2006. As Executive Director a.i, he has led Unitaid's response to the COVID-19 pandemic, playing a vital role as the co-lead of the therapeutics arm of the Access to COVID Tools Accelerator. Previously, he was a practicing doctor at Hospital "La Pitié Salpêtrière" in Paris (Infections Diseases Department) and was twice advisor to the French Ministry of Health under Minister Bernard Kouchner. He was the head of the Mission against HIV/AIDS and harm reduction for l'Assistance publique – Hôpitaux de Paris (AP-HP) and led the French regulatory agency for medicines and health products. He also chaired the Board of the European Medicines Agency. Philippe holds a Master's degree in Public Health and is a medical Doctor.</p>
<b>Dr Lynda Stuart</b>	<p>Lynda Stuart is a physician-scientist with over 20 years of experience in immunology, global health, and product development. She serves as President and Chief Executive Officer of Fund for Science and</p>



International  
Pandemic  
Preparedness  
Secretariat

**anrs**  
MALADIES INFECTIEUSES  
EMERGENTES Inserm

 **PASTEUR**  
NETWORK



Technology (FFST), a new private foundation focused on advancing the fields of artificial intelligence, bioscience, and the environment to create lasting impact that benefits people and the planet.

She was previously Executive Director of the Institute for Protein Design (IPD) at the University of Washington School of Medicine, Vice President of Infectious Disease at BioNTech, and Deputy Director Global Health at Bill & Melinda Gates Foundation, where she oversaw the preclinical development of vaccines and antibody therapies. Stuart is also an affiliate professor at Benaroya Research Institute at Virgina Mason, a member of the Scientific Advisory Council to the Coalition for Epidemic Preparedness and Innovation and a member of the Science and Technology Expert Group of the 100 Days Mission.

#### **Daphne von Buxhoeveden**



Daphne von Buxhoeveden, based in Brussels, is currently a Head of Unit in DG HERA at the European Commission. Prior to that she was member of the Cabinet of Commissioner Stella Kyriakides. Daphne von Buxhoeveden brings experience from previous roles at the European Commission, the UK Government and the private sector. She holds a Master of Science (MSc) in Natural Resource and Environmental Economics from the University College London and a Master of Arts degree in Economics and Politics from the University of Edinburgh.



**Dr Ruxandra Draghia-Akli**



Ruxandra Draghia-Akli, MD, PhD, is the Executive Vice President and Head of Research & Development (R&D) in Novavax, ensuring the company is maximizing the tremendous potential of Novavax's proven technology, including the Matrix-M™ adjuvant. She is the chair of the Scientific Advisory Board of INTREPID Alliance, an organization focused on accelerating small molecule antiviral R&D.

Dr. Draghia-Akli previously served at Johnson & Johnson, as Global Head of Global Public Health R&D, and Merck, Inc. delivering groundbreaking innovations in drugs and vaccines to address climate-related, emerging and entrenched health threats. She also worked with the European Commission, supporting programmatic, legislative, regulatory and policy issues in medical research and innovation. Over her career, Dr. Draghia has authored many scientific publications and served on numerous boards and committees to help shape thinking on vaccine and public health issues. Dr. Draghia-Akli received an MD from the University of Medicine Carol Davilla, Romania and a PhD in human genetics from the University of Medicine Carol Davilla and undertook additional doctoral and post-doctoral training at University Rene Descartes, France and Baylor College of Medicine, USA respectively.

**Dr Kelly Chibale**



Kelly Chibale is a Professor of Organic Chemistry at the University of Cape Town (UCT) where he holds the Neville Isdell Chair in African-centric Drug Discovery & Development. He is also a Schmidt Sciences AI2050 Senior Fellow, Full Member of the UCT Institute of Infectious Disease & Molecular Medicine, founding Director of the South African Medical Research Council Drug Discovery & Development Research unit at UCT, and Founder & Director of the UCT Holistic Drug Discovery and Development (H3D) Centre and Founder and CEO of the H3D Foundation.

Kelly obtained his PhD in Synthetic Organic Chemistry from the University of Cambridge. This was followed by postdoctoral stints at the University of Liverpool and Scripps Research Institute.

Kelly's research interests are in infectious disease drug discovery and the development of technologies to contribute to improving treatment outcomes in people of African descent.

He serves as Editor-In-Chief of the American Chemical Society (ACS)'s ACS Medicinal Chemistry Letters.



**Dr Ifedayo Adetifa**



Dr Ifedayo Adetifa, a seasoned pediatrician and accomplished infectious disease epidemiologist, has served as the CEO of FIND, the global leader in diagnostics, since September 2024. Prior to joining FIND, he was the Director-General of the Nigeria Centre for Disease Control & Prevention (NCDC).

Dr Adetifa's background includes work on vaccine preventable diseases, and outbreak-prone pathogens. Dr Adetifa has also been an associate professor at the London School of Hygiene and Tropical Medicine, and clinical epidemiologist at the KEMRI-WELLCOME Trust Research Programme in Kenya.

**Dr Beth Cameron**



Dr. Elizabeth (Beth) Cameron is a Professor of the Practice and Senior Advisor to the Pandemic Center at the Brown University School of Public Health. In addition to her role with the Pandemic Center, Beth is a non-resident senior advisor to the Center for Strategic and International Studies (CSIS) Global Health Policy Center, a life member of the Council on Foreign Relations, and a practitioner senior fellow of the UVA Miller Center.

Beth is a global leader in health security, biosecurity, pandemic preparedness, biodefense, and combating bioterrorism. She has served over two decades, within and outside of government, to facilitate change. She spent two tours on the White House National Security Council staff, twice helping establish and lead the Directorate on Global Health Security and Biodefense, a role in which she served under three Presidents. In this and other positions, she builds and leads robust teams focused, every day, on leaning forward to prevent, detect, and rapidly respond to biological crises. Beth has held senior posts at the Departments of State and Defense, where she created and oversaw biological and chemical security efforts, as well as the U.S. Agency for International Development where she served as a global health security adviser.



	<p>Outside of government, she served as a Vice President of the Nuclear Threat Initiative, where she was an architect of NTI   bio, a program aimed at countering biological catastrophes, and she served at the American Cancer Society. She has been instrumental to developing, coordinating, launching, and implementing the U.S. global COVID-19 response, the Pandemic Fund, the U.S. National Biodefense Strategy, the Global Health Security Agenda, the Development Finance Institutions Medical Countermeasures Surge Financing Initiative, the Global Partnership Against the Spread of Weapons and Materials of Mass Destruction biosecurity effort, and many other initiatives focused on improving biosecurity and biosafety globally. Her work has helped address homeland and national security threats by enhancing pandemic preparedness, biosecurity and biosafety; improving emerging infectious disease surveillance, and countering the development and use of biological weapons.</p> <p>She got her start in government as an AAAS fellow at the State Department and in the office of Senator Edward M. Kennedy. Beth holds a Ph.D. in Biology from the Human Genetics and Molecular Biology Program at the Johns Hopkins University and a B.A. in Biology from the University of Virginia.</p>
<b>Dr Jillian Sacks</b> 	<p>Jillian A. Sacks, Ph.D. is the Director of Global Health Policy at Roche Diagnostics, where she leads strategic efforts to shape global health frameworks and expand patient access to diagnostic innovation. An immunologist by training, she has worked for over a decade on the introduction and scale-up of diagnostic solutions in low-resource settings. Prior to joining Roche in 2023, Dr. Sacks was a Technical Officer at the World Health Organization (WHO), where she contributed to the development of evidence-based testing strategies and policy during acute emergencies, including COVID-19 and mpox. Her experience includes roles at FIND and the Clinton Health Access Initiative (CHAI) focused on infectious diseases, pandemic preparedness, and health equity. She holds a Ph.D. in Immunology and has a clinical research background in biomarkers and diagnostics from Rutgers University and the Africa Health Research Institute.</p>
<b>Prof Bruno Lina</b>	<p>Born in Lyon in 1961, Bruno Lina graduated MD in 1990 and PhD in 1996. He is Professor of Virology in at the Université de Lyon, head of the Institut des Agents Infectieux and the Virology lab of the Hospices Civils de Lyon, director of the National Influenza Centre (France), Member of COVINET for WHO since 2023, and head of the « VIRPATH » team in the U1111 INSERM CIRI research Centre. He has been elected President of the University Claude Bernard Lyon 1 in March 2025. He is a scientific expert for the French</p>



International  
Pandemic  
Preparedness  
Secretariat

anrs  
MALADIES INFECTIEUSES  
EMERGENTES Inserm

PASTEUR  
NETWORK



Ministry of Health, and has been temporary expert for WHO and ECDC several times. He has carried out expert evaluations for national (AERES, ANSES, INSERM) and international bodies (NIH, HKU, ECDC and WHO). He has been Chair of the WHO PIP Advisory Group for sharing of viruses and Benefits (2008-2010). He has been a member of the ECDC ERLI-Net network coordination committee for 9 years (until 2020), and is a member of the ECDC EUPHEM advisory forum. Bruno LINA has been President of the ECSV. He has been a member of the scientific committees of the ESV and ESWI. He is chairing the Global Influenza and RSV Initiative and Immuniser.Lyon programs. He has published 490 peer reviewed international articles (H index : 61 ISI web of Science; N° ORCID : 0000-0002- 8959-2123; Research ID : M-4572-2014), several book chapters and books.

#### Prof Leo Poon



Professor Poon, a virologist and public health scientist, received his PhD from the Sir William Dunn School of Pathology at the University of Oxford. In 2001, he joined the University of Hong Kong (HKU) as a Research Assistant Professor and is now the Chair Professor in the School of Public Health, also serving as co-director of the HKU-Pasteur Research Pole and co-director of the Hong Kong Jockey Club Global Health Institute (HKJCGHI).

Professor Poon's research primarily focuses on emerging and re-emerging viruses that threaten human health, including SARS-CoV, SARS-CoV-2, MERS-CoV, and zoonotic influenza viruses. Utilizing the "One Health" concept, he studies viruses at the animal-human interface and has developed molecular tests for various zoonotic viruses. Notably, he contributed to the discovery of the coronavirus responsible for SARS in 2003 and decoded its sequence, leading to the identification of coronaviruses in wildlife, including the first bat coronavirus. During the H1N1 pandemic in 2009, he identified the first reassortant of the pandemic virus in pigs. His work during the COVID-19 pandemic significantly advanced our understanding of SARS-CoV-2 and its public health implications, and he has a strong interest in vaccinology.



International  
Pandemic  
Preparedness  
Secretariat

anrs  
MALADIES INFECTIEUSES  
EMERGENTES Inserm

PASTEUR  
NETWORK

### Dr Hervé Raoul



Hervé Raoul is Director of Research at Inserm and Deputy Director of the ANRS-MIE (ANRS – Emerging Infectious Diseases) since July 2021. He has been Director of the Inserm Jean Mérieux BSL4 laboratory located in Lyon from October 2005 to September 2022. He is and has been actively involved in various international collaborations and in European-funded programs and has created in July 2017 the pan-European infrastructure dedicated to RG4 pathogens study. He is also the coordinator of the future European Pandemic Preparedness Partnership He is member of various national and international scientific advisory boards.

PhD in Biology of Blood Cells (1995, University of Paris 7, France)  
Accreditation to supervise research (HDR) in Toxicology (2000, University of Paris XI, France).

### Prof Mario Moreira



At the Oswaldo Cruz Foundation (Fiocruz) since 1994, Mario Moreira holds a PhD in Public Policy from the Federal University of Paraná, with a doctoral internship at the University of Coimbra, Portugal. He also holds master's degrees in Public Health from the Sergio Arouca National School of Public Health (ENSP/Fiocruz) and in Technology and Innovation Management from the University of Sussex, United Kingdom. In addition, he earned an MBA in Public Administration from the Getulio Vargas Foundation. In 2017, he was appointed Vice President of Management and Institutional Development at Fiocruz. He was elected President of Fiocruz in 2023 and subsequently re-elected for the 2025–2028 term. Dr. Moreira serves as the representative of the Region of the Americas on the Board of Directors of the Pasteur Network; is a member of the Steering Committee of the International Pandemic Preparedness Secretariat (IPPS); Chair of the Strategic Advisory Group on Strengthening Regional Innovation and Manufacturing Capacities for Medicines and Other Health Technologies at the Pan American Health Organization; member of the Emergency Advisory Group at the Africa Centres for Disease Control and Prevention; Chair of the Assembly of the Paraná Institute of Molecular Biology (IBMP); and President of the Pasteur Network.



International  
Pandemic  
Preparedness  
Secretariat

anrs  
MALADIES INFECTIEUSES  
EMERGENTES Inserm

PASTEUR  
NETWORK

### Dr Melanie Saville



Melanie Saville, MBBS, is PATH's Chief Scientific Officer. She leads PATH's product development division, which includes a global team dedicated to the development, introduction, and scale of vaccines, medical devices, and diagnostics.

Dr. Saville is a distinguished physician specializing in virology with more than two decades of experience developing and licensing vaccines for global use. Her contributions over the past 20 years have included the development of vaccines for seasonal and pandemic influenza, as well as pediatric combinations and vaccines against rabies, Japanese encephalitis, dengue, Ebola, and SARS-CoV-2.

Before joining PATH, Dr. Saville worked with the Coalition for Epidemic Preparedness Innovations (CEPI), where she served as the Executive Director of Vaccine Research and Development, leading technical teams supporting vaccine development. She also served as the R&D and manufacturing workstream leader for COVAX, part of a global collaboration to speed development, production, and equitable access to COVID-19 tests, treatments, and vaccines.

Dr. Saville holds a medical degree, a master's degree in medical virology, and a Bachelor of Science in molecular biology from University College, London.

### Dr Eric Quéméneur



Eric Quéméneur (PharmD, PhD, HDR) is the Director of the French initiative for vaccine research and development. This large R&D program aims at accelerating the transfer of most advanced vaccines candidates designed in academic labs from preclinical research to clinical and preindustrial development. He will bring his experience of collaborative R&D with the biotech and pharma industry ; 20 years at CEA, in the field of protein engineering, and toxicology; 10 years as CSO of Transgene in the field of cancer immunotherapy. He is also actively involved in entrepreneurship and innovation, currently advising 3 start-up companies, and chairing the SAB of INOV3PT.



International  
Pandemic  
Preparedness  
Secretariat

anrs  
MALADIES INFECTIEUSES  
EMERGENTES Inserm

PASTEUR  
NETWORK

### Dr Aurélia Nguyen



Aurélia Nguyen joined CEPI in October 2024 as Deputy CEO based in the London office. In this role, Aurélia is in charge of shaping and delivering on CEPI's priorities across the organization for CEPI to reach its mission to accelerate the development of vaccines and other biologic countermeasures against epidemic and pandemic threats.

Prior to joining CEPI, Aurélia spent 13 years at Gavi, the Vaccine Alliance – latterly managing all of Gavi's programmatic work as Chief Programme Officer, with responsibility for design and execution of GAVI's vaccine programmes. During her tenure at Gavi, Aurélia served as Managing Director of the Office of the COVAX Facility, set up in 2020 in response to the COVID-19 pandemic.

Earlier in her career, Aurélia held various posts within GlaxoSmithKline, contributing to the development of their policies on access to medicines and vaccines in Lower and Middle-Income Countries, and also within WHO, undertaking research on generic medicines policies.

Aurélia has served on a number of boards, including the Polio Oversight Board and the International Planned Parenthood Federation (IPPF)'s Board of Trustees.

Aurélia is a certified accountant and holds a Master's degree in Health Policy, Planning & Financing from the London School of Hygiene & Tropical Medicine and the London School of Economics. She received the Medal of Friendship by Vietnamese Prime Minister Pham Minh Chinh in 2023 and was featured in TIME Magazine's 2021 TIME100 Next list honouring "the 100 individuals who are shaping the future of their fields and defining the next generation of leadership".



International  
Pandemic  
Preparedness  
Secretariat

**anrs**  
MALADIES INFECTIEUSES  
EMERGENTES Inserm

 **PASTEUR**  
NETWORK

**Dr Katherine Theiss-Nyland**



Dr. Katherine Theiss-Nyland is the Global Evidence Generation Lead for RSV vaccines at GSK, where she directs real-world evidence strategies to advance vaccine benefits across diverse populations and settings. With over 20 years in public health, Katherine's career spans leadership roles in international NGOs, government agencies, and academia, focusing on infectious diseases, vaccines, and maternal and child health. She has led multi-country research and implementation programs, notably as Technical Director at the Malaria Consortium, Typhoid programme coordinator at the Oxford Vaccine Group, and as Real World Evidence Lead for Vaccines at Janssen, shaping evidence generation for Typhoid, Malaria, COVID-19 and RSV vaccines.

Katherine's work has bridged community health in Africa, technical advising for WHO, and vaccine trials with the University of Oxford, fostering partnerships to inform policy and equitable access. Her experience collaborating with governments, donors, and NGOs in over a dozen countries positions her as a passionate advocate for vaccine equity and global health innovation. Katherine holds a PhD in Infectious Disease Epidemiology from the London School of Hygiene and Tropical Medicine and an MPH from UC Berkeley.

**Ms Eloise Todd**



Eloise Todd is an advocacy, policy, campaigns, and strategy specialist with over 20 years' experience working to change policies, legislation and budgets to improve lives. She is the Executive Director and Founder of rani, which coordinates advocacy to build societal resilience to shifts, change, and crisis.



International  
Pandemic  
Preparedness  
Secretariat

**anrs**  
MALADIES INFECTIEUSES  
EMERGENTES Inserm

 **PASTEUR**  
NETWORK

### Dr Kerri Elgar



Kerri Elgar is a senior advisor on Global Health at the Organisation for Economic Co-operation and Development and the OECD's representative on the Working for Health Secretariat. Her current work is focused on strengthening health system resilience against health shocks, including in the context of pandemic preparedness and response, universal health coverage and health workforce.

Since joining the OECD, she has led cross-policy research on range of topics including global public goods and vaccine equity and also worked in co-ordination roles for the G20 and G7, including at the OECD G20/G7 Sherpa Office. Previously, she worked for AusAID and the Australian Government's Department of Foreign Affairs and Trade, including as an Advisor in the office of former Australian Prime Minister and Foreign Affairs Minister Kevin Rudd and as a representative to the G20 Development Working Group.

Kerri holds a PhD from the University of Queensland and has lectured on crisis management and ethics in universities in Australia, France and Papua New Guinea.

### Dr Claude Muvunyi



Prof. Claude Mambo MUVUNYI is the Director General of Rwanda Biomedical Centre. He has more than 15 years of scientific, technical, and leadership expertise in strategic planning, management, innovation, and implementation in public health and healthcare at international, regional, national levels. He has a substantial expertise in clinical and public laboratory medicine with special focus on clinical microbiology, enhancing laboratory systems and services, health system strengthening, and global health security improvement. Prof. MUVUNYI is currently a full professor of clinical Microbiology and Laboratory Medicine at the University of Rwanda. He holds a degree in general medicine from the University of Rwanda, a specialization and a PhD in Clinical Microbiology from the University of Ghent, Belgium. He also holds a master's in medical Virology from the University of Manchester. Prior to joining the RBC, Prof. MUVUNYI was a Senior Regional Laboratory Advisor at ICAP at Columbia University, providing technical and strategic leadership support to the Laboratory program/project in building



International  
Pandemic  
Preparedness  
Secretariat

**anrs**  
MALADIES INFECTIEUSES  
EMERGENTES Inserm

 PASTEUR  
NETWORK

	<p>quality assured diagnostic capacities at all levels in the network (public and private health laboratories). He has also been a senior consultant for World Health Organization (WHO) supporting WHO's programs for Antimicrobial Resistance (AMR) surveillance and diagnostic capacity building for infectious disease in African countries. He has been the Head of National Reference Laboratory, and the Director of Microbiology Unit as well as a study physician for AIDS Vaccine clinical and feasibility research at Project San Francisco. In this Project, Prof Claude provided oversight and strategic.</p> <p>Prof. MUVUNYI research interests include Health Systems Analysis and Strengthening, Integrated surveillance systems for monitoring and tracking burdens of diseases and risks factors, Prevention and Control of emerging diseases and risk factors, investigating and reducing socioeconomic burdens of diseases, and developing and implementing innovative approach for the prevention and control of diseases. He is also interested in improving the current understating the resistance mechanics in bacterial infection and evaluation of diagnostic methods (molecular and serological) for infectious diseases as well as operational research on diagnostic implementation and scale up to assess the impact of the new diagnostic for infectious diseases.</p>
<b>Dr Claire Rieux</b> 	<p>Claire Rieux is a clinical haematologist, with a master's degree in public health and epidemiology. She worked for several years in clinical hematology at university hospitals in Lyon and Paris, before contributing to the structuring of hemovigilance and healthcare risk management. With Médecins Sans Frontières (MSF), she carried out several missions as field doctor and medical coordinator. She was elected to the Board of Directors of MSF France from 2008 to 2014 and served as Vice-President for 3 years. In 2016 she initiated projects with MSF dedicated to women's cancers. Since 2022, she is the Medical Director of MSF France.</p>